Jana L Mannan, MD
Obstetrics/Gynecology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 23
- 5 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
23 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mannan’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
23 of 23 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A67770 · Current
Licensed to practise in California · since 1999 · expires 2027-01-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$2,276,837 in 2024
Medicaid paid $2,276,837 for 48,750 billed services this clinician did in 2024, up to 419 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 4,207 | $2,172,995 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 720 | $33,335 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 290 | $8,960 |
| Short return visit (20+ min) | 3,477 | $7,873 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 722 | $5,492 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 719 | $5,485 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique | 306 | $5,240 |
| Return visit (30+ min) | 1,758 | $4,821 |
| Long return visit (40+ min) | 1,043 | $4,248 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 304 | $3,384 |
| Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result | 513 | $2,855 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 549 | $2,610 |
| 2024 | 48,750 | 74 | 419 | $2,276,837 |
| 2023 | 18,682 | 53 | 315 | $2,003,694 |
| 2022 | 5,933 | 23 | 188 | $808,560 |
| 2021 | 1,770 | 14 | 80 | $378,893 |
| 2020 | 1,211 | 8 | 66 | $276,797 |
| 2019 | 911 | 6 | 74 | $274,444 |
| 2018 | 5,849 | 23 | 219 | $1,088,257 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 3,828 | $1,927,421 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 345 | $11,241 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 279 | $11,108 |
| Short return visit (20+ min) | 3,309 | $10,324 |
| Return visit (30+ min) | 1,846 | $9,150 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 594 | $5,325 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 593 | $5,277 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique | 283 | $4,646 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 286 | $2,973 |
| Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result | 293 | $2,822 |
| Long return visit (40+ min) | 422 | $2,764 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 345 | $2,080 |
2022
| Clinic visit/encounter, all-inclusive | 1,581 | $782,287 |
| Short return visit (20+ min) | 1,487 | $6,633 |
| Return visit (30+ min) | 786 | $4,851 |
| OBSTETRICAL CARE | 13 | $4,458 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 124 | $1,976 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 124 | $1,970 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 35 | $1,968 |
| Long return visit (40+ min) | 141 | $1,221 |
| Short return visit | 167 | $567 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 103 | $526 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 12 | $418 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique | 12 | $365 |
2021
| Clinic visit/encounter, all-inclusive | 776 | $376,645 |
| Short return visit (20+ min) | 369 | $1,020 |
| Short return visit | 197 | $581 |
| Return visit (30+ min) | 132 | $284 |
| Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result | 29 | $186 |
| Long return visit (40+ min) | 14 | $62 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 40 | $31 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 14 | $27 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 13 | $27 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 24 | $26 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 56 | $5 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 33 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 739 | $275,030 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 84 | $1,039 |
| Return visit (30+ min) | 64 | $355 |
| Short return visit (20+ min) | 161 | $150 |
| Short return visit | 116 | $150 |
| FETAL NON-STRESS TEST | 15 | $61 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 14 | $11 |
| URINE PREGNANCY TEST | 18 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 698 | $272,402 |
| Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses | 16 | $913 |
| Return visit (30+ min) | 140 | $572 |
| FETAL NON-STRESS TEST | 28 | $489 |
| Short return visit (20+ min) | 16 | $52 |
| URINE PREGNANCY TEST | 13 | $17 |
2018
| Clinic visit/encounter, all-inclusive | 2,860 | $1,074,301 |
| Short return visit (20+ min) | 896 | $3,966 |
| Return visit (30+ min) | 503 | $3,820 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 309 | $1,863 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 309 | $1,857 |
| FETAL NON-STRESS TEST | 66 | $707 |
| Service | 13 | $282 |
| Service | 15 | $175 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 45 | $162 |
| Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result | 13 | $161 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 154 | $157 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 144 | $149 |
Drugs they prescribed that Part D paid
$8,723
Pharmacies billed $8,723 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
61 generic and fewer than 11 brand-name prescriptions · $8,723 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 11 | $1,307 | $119 |
| Heather | 13 | $81 | $6 |
Year by year
| 2024 | 71 | 24 | None | None | $8,723 |
| 2023 | 51 | 15 | 0% (0) | None | $7,824 |
| 2022 | 65 | 19 | 0% (0) | 23% | $10,234 |
| 2021 | 77 | 23 | 0% (0) | 25% | $10,025 |
| 2020 | 95 | 26 | 0% (0) | 14% | $10,717 |
| 2019 | 76 | 18 | None | None | $7,619 |
| 2018 | 117 | 30 | None | None | $11,773 |
| 2017 | 160 | 37 | None | 19% | $17,531 |
| 2016 | 123 | 33 | 0% (0) | 16% | $8,518 |
| 2015 | 99 | 23 | None | 18% | $7,700 |
| 2014 | 116 | 27 | None | 41% | $10,166 |
| 2013 | 66 | 19 | None | 58% | $4,667 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Heather | 13 | $279 | $21 |
2022: 1 drug
| Heather | 13 | $272 | $21 |
2021: 2 drugs
| Estradiol | 15 | $2,243 | $150 |
| Heather | 13 | $268 | $21 |
2020: 2 drugs
| Estrace | 11 | $4,272 | $388 |
| Heather | 13 | $317 | $24 |
2019: 2 drugs
| Estrace | 12 | $3,998 | $333 |
| Heather | 13 | $206 | $16 |
2018: 2 drugs
| Estrace | 17 | $6,327 | $372 |
| Heather | 26 | $418 | $16 |
2017: 4 drugs
| Estrace | 14 | $4,380 | $313 |
| Oxybutynin Chloride Er | 14 | $877 | $63 |
| Estradiol | 17 | $345 | $20 |
| Norethindrone | 18 | $297 | $17 |
2016: 3 drugs
| Oxybutynin Chloride Er | 20 | $848 | $42 |
| Norethindrone | 23 | $523 | $23 |
| Estradiol | 13 | $119 | $9 |
2015: 3 drugs
| Oxybutynin Chloride Er | 13 | $1,569 | $121 |
| Errin | 17 | $310 | $18 |
| Norethindrone | 14 | $286 | $20 |
2014: 1 drug
| Heather | 21 | $502 | $24 |
2013: 1 drug
| Nora-Be | 19 | $475 | $25 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1750348710
- Licence
- CA A67770California A67770: Current · expires 2027-01-31
- Trained
- Stanford University School of Medicine, 1997
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A677700
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 751 S Bascom Ave, San Jose, CA, 95128
- NPI first listed
- 2006-04-26
- NPI last updated
- 2007-09-11
This is when the NPI record was last certified, not a medical board exam.